FDA White Oak Campus, 10903 New Hampshire Avenue, Silver Spring, Maryland, 20993, United StatesImmunityBio
SCHEDULEDDate confidence: SCHEDULEDGiven as scheduledHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all SCHEDULED pins75% CONFIDENCEOverall confidence: 75%How well the pin's source and references back up its dates.Weighted average of how firmly 4 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins at 75% confidence or betterImmunityBio's[1][2] release says the FDA "assigned a PDUFA target action date of January 6, 2027" for the supplemental BLA.
The FDA has assigned a 6 January 2027 PDUFA target date for ImmunityBio's supplemental BLA for Anktiva plus BCG in BCG-unresponsive non-muscle invasive bladder cancer with papillary disease.
1.00